VERU News and Press, Veru Inc. From 02/27/23

Summary Veru Inc. is eyeing emergency use authorization for its COVID-19 drug Sabizabulin, which is currently under FDA review. Veru Inc. shares fell around 20% to a 52-week low after reporting Q1 FY23 results that fell short of analysts' revenue forecasts. Veru's future lies in obt...

Veru Inc. (VERU) Q1 2023 Earnings Conference Call February 09, 2023 08:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - C...

Veru Inc. ( NASDAQ: VERU ) shares lost ~20% in the morning hours Thursday to reach a 52-week low after falling short of Street forecasts for its Q1 FY23 results, particularly in relation to revenue. The maker of FC2 Female Condom reported $2.5M in revenue for the quarter with a ~8...

Veru press release ( NASDAQ: VERU ): Q1 GAAP EPS of -$0.46 misses by $0.08 . Revenue of $2.51M (-82.2% Y/Y) misses by $2.56M . Cash and cash equivalents were $46.9 million as of December 31, 2022 versus $80.2 million as of September 30, 2022 Net accounts receivable...

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin treatment resulted in 81.2% relative reduction in deaths compared to the placebo in the WHO 4...

Veru ( NASDAQ: VERU ) is scheduled to announce Q1 earnings results on Thursday, February 9th, before market open. The consensus EPS Estimate is -$0.38 (-375.0% Y/Y) and the consensus Revenue Estimate is $5.07M (-64.1% Y/Y). Over the last 1 year, VERU has beaten EPS estimates...

MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9, 2...

Boston, Massachusetts--(Newsfile Corp. - January 18, 2023) - Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for se...

New York, New York--(Newsfile Corp. - January 16, 2023) - Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit. The lawsuit on behalf of Veru investors has been commenced in the the United States District Court ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: MEE KO DONG / Shutterstock.com One of last year’s surprise hits in the biotech sphere, Veru (NASDAQ: VERU ) is making headlines once again today. Currently, VERU stock is up 8%. Known for its Covid-19 the...